After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...

Consumer healthcare last year ... by what it calls digestive wellness. Sanofi in last year’s annual results said Dulcolax was ...

Sanofi's Consumer Healthcare division, Opella, announced that the U.S. Food and Drug Administration has lifted a clinical hold on its ...

The US Food and Drug Administration (FDA) has removed the clinical hold on a trial of Cialis (tadalafil) by Sanofi's consumer ...

Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank ...

Sanofi’s (SNY) said FDA lifted a hold on a trial to test over-the-counter use of its Eli-Lilly (LLY)-partnered erectile ...

Within the atopic dermatitis (AD) field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration ...

Sanofi Consumer Healthcare India Ltd share price was up by 0.03% from the previous closing price of ₹4,821.65. Who are peers of Sanofi Consumer Healthcare India Ltd? The peers of Sanofi Consumer ...

The trial enrolled 531 adult subjects with multiple myeloma who had received at least one previous line of therapy.

Sanofi India's Consumer Healthcare Business Unit has a strong presence in four segments, namely pain-care, digestive health, allergy solutions, and vitamins, minerals and supplements. The ...

Sanofi Consumer Healthcare India Limited was incorporated on May 10, 2023, pursuant to a Certificate of Incorporation, issued by the Registrar of Companies, Central Registration Centre.